148 related articles for article (PubMed ID: 24397527)
1. Environmental risk assessment of replication competent viral vectors applied in clinical trials: potential effects of inserted sequences.
van den Akker E; van der Vlugt CJ; Bleijs DA; Bergmans HE
Curr Gene Ther; 2013 Dec; 13(6):395-412. PubMed ID: 24397527
[TBL] [Abstract][Full Text] [Related]
2. Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.
Goossens M; Pauwels K; Willemarck N; Breyer D
Curr Gene Ther; 2013 Dec; 13(6):413-20. PubMed ID: 24397528
[TBL] [Abstract][Full Text] [Related]
3. General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination.
Baldo A; van den Akker E; Bergmans HE; Lim F; Pauwels K
Curr Gene Ther; 2013 Dec; 13(6):385-94. PubMed ID: 24195604
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.
Wold WS; Toth K
Curr Gene Ther; 2013 Dec; 13(6):421-33. PubMed ID: 24279313
[TBL] [Abstract][Full Text] [Related]
5. Biosafety challenges for use of lentiviral vectors in gene therapy.
Rothe M; Modlich U; Schambach A
Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
[TBL] [Abstract][Full Text] [Related]
6. Biosafety of viral vectors commonly used in gene therapy and vaccination.
Herman P
Curr Gene Ther; 2013 Dec; 13(6):383-4. PubMed ID: 24397526
[No Abstract] [Full Text] [Related]
7. Can the use of HIV-1 derived gene transfer vectors for clinical application be justified?
Fuller M; Anson DS
Curr Gene Ther; 2004 Mar; 4(1):65-77. PubMed ID: 15032615
[TBL] [Abstract][Full Text] [Related]
8. Biosafety of gene therapy vectors derived from herpes simplex virus type 1.
Lim F; Khalique H; Ventosa M; Baldo A
Curr Gene Ther; 2013 Dec; 13(6):478-91. PubMed ID: 24397529
[TBL] [Abstract][Full Text] [Related]
9. Biosafety considerations using gamma-retroviral vectors in gene therapy.
Deichmann A; Schmidt M
Curr Gene Ther; 2013 Dec; 13(6):469-77. PubMed ID: 24195605
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus vectors deleted for genes essential for viral DNA replication.
Schaack J
Front Biosci; 2005 May; 10():1146-55. PubMed ID: 15769613
[TBL] [Abstract][Full Text] [Related]
11. Biosafety of recombinant adeno-associated virus vectors.
Dismuke DJ; Tenenbaum L; Samulski RJ
Curr Gene Ther; 2013 Dec; 13(6):434-52. PubMed ID: 24195602
[TBL] [Abstract][Full Text] [Related]
12. Insertion of sequences into the 3' untranslated region of a replication-competent spleen necrosis virus vector disrupts env gene expression.
Yin PD; Hu WS
Arch Virol; 1999; 144(1):73-87. PubMed ID: 10076510
[TBL] [Abstract][Full Text] [Related]
13. Replication-defective genomic herpes simplex vectors: design and production.
Burton EA; Bai Q; Goins WF; Glorioso JC
Curr Opin Biotechnol; 2002 Oct; 13(5):424-8. PubMed ID: 12459332
[TBL] [Abstract][Full Text] [Related]
14. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?
Bear AS; Morgan RA; Cornetta K; June CH; Binder-Scholl G; Dudley ME; Feldman SA; Rosenberg SA; Shurtleff SA; Rooney CM; Heslop HE; Dotti G
Mol Ther; 2012 Feb; 20(2):246-9. PubMed ID: 22297819
[No Abstract] [Full Text] [Related]
15. Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines.
Dalba C; Bellier B; Kasahara N; Klatzmann D
Mol Ther; 2007 Mar; 15(3):457-66. PubMed ID: 17245356
[TBL] [Abstract][Full Text] [Related]
16. Mucosal vaccine vectors: replication-competent versus replication-deficient poxviruses.
Karkhanis LU; Ross TM
Curr Pharm Des; 2007; 13(19):2015-23. PubMed ID: 17627535
[TBL] [Abstract][Full Text] [Related]
17. Comparative analyses of transgene delivery and expression in tumors inoculated with a replication-conditional or -defective viral vector.
Ichikawa T; Chiocca EA
Cancer Res; 2001 Jul; 61(14):5336-9. PubMed ID: 11454670
[TBL] [Abstract][Full Text] [Related]
18. A replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based lentiviral vectors.
Miskin J; Chipchase D; Rohll J; Beard G; Wardell T; Angell D; Roehl H; Jolly D; Kingsman S; Mitrophanous K
Gene Ther; 2006 Feb; 13(3):196-205. PubMed ID: 16208418
[TBL] [Abstract][Full Text] [Related]
19. Construction and production of oncotropic vectors, derived from MVM(p), that share reduced sequence homology with helper plasmids.
Clément N; Velu T; Brandenburger A
Cancer Gene Ther; 2002 Sep; 9(9):762-70. PubMed ID: 12189526
[TBL] [Abstract][Full Text] [Related]
20. Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications.
Advani SJ; Weichselbaum RR; Whitley RJ; Roizman B
Clin Microbiol Infect; 2002 Sep; 8(9):551-63. PubMed ID: 12427216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
